Clinical Trial Update: Reaching Protein Target With SmofKabiven® Extra Nitrogen vs Olimel N9E During the Early Phase of Acute Critical Illness [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial comparing SmofKabiven Extra nitrogen versus Olimel N9E in the early phase of acute critical illness was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Illness

Drugs mentioned

• Olimel N9E
• SmofKabiven Extra

Snippet

Sponsor: Fresenius Kabi | Conditions: Critical Illness | Phase 4 | Status: TERMINATED